[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100565910":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":12,"centralContacts":17,"locations":26,"responsibleParty":45,"collaborators":7,"id":48,"slug":49,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":7,"eligibilityCriteria":53,"healthyVolunteers":50,"sex":54,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":60,"studyType":61,"phases":7,"briefSummary":62,"conditions":63,"keywords":7,"overallStatus":28,"whyStopped":7,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},{"fullName":5,"class":6},"Peking University Cancer Hospital & Institute","OTHER",null,[9],{"type":6,"name":10,"description":11,"armGroupLabels":7,"otherNames":7},"FDG-PET","All study participants will undergo 18F-FDG PET\u002FCT scan within 1 week",[13],{"name":14,"affiliation":15,"role":16},"Nan Li, MD","Peking University Cnacer Hospital & Institute","PRINCIPAL_INVESTIGATOR",[18,23],{"name":19,"role":20,"phone":21,"phoneExt":7,"email":22},"Nan Li","CONTACT","+86-13693090647","rainbow6283@sina.com",{"name":24,"role":20,"phone":7,"phoneExt":7,"email":25},"Xin Zhou, MD","zhouxinbjmu@163.com",[27],{"facility":5,"status":28,"city":29,"state":30,"zip":31,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"RECRUITING","Beijing","Beijing Municipality","100142","China","CN",{"type":35,"coordinates":36},"Point",[37,38],116.39723,39.9075,{"lat":38,"lon":37},[41,44],{"name":14,"role":20,"phone":42,"phoneExt":7,"email":43},"+86-010-88197852","rainbow6293@sina.com",{"name":24,"role":20,"phone":42,"phoneExt":7,"email":25},{"type":16,"investigatorFullName":46,"investigatorTitle":47,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"nanli","Professor","100565910","radiolabelled-nectin-4-targeted-lmw-probe-petct-in-patients-with-lung-lesions-100565910",false,"NCT06648317","Radiolabelled Nectin-4 Targeted LMW Probe PET\u002FCT in Patients With Lung Lesions","Inclusion Criteria:\n\n1. 18-75 years old, male or female;\n2. Heart function is normal;\n3. Normal heart function;\n4. Estimated survival ≥12 weeks;\n5. Good follow-up compliance;\n6. presence of at least one measurable target lesion according to RECIST1.1 criteria;\n7. Women of childbearing age (15-49 years) must have a negative pregnancy test within 7 days before starting the test; Fertile men and women must agree to use effective contraception to prevent pregnancy during the study period and for 3 months after the test;\n8. Patients recommended by clinicians to undergo PET\u002FCT examination for tumor diagnostic staging;\n9. The subject patients could fully understand and voluntarily participate in the experiment, and signed the informed consent.\n\nExclusion Criteria:\n\n1. Serious abnormality of liver, kidney and blood;\n2. Pregnant patients;\n3. Pregnant and lactation women;\n\n3\\) unable to lie flat for half an hour; 4) Refuse to join the clinical investigator; 5) Suffering from claustrophobia or other mental diseases; 6) Other conditions that researchers deem unsuitable for participating in the experiment.","ALL","18 Years","75 Years",{"count":58,"type":59},20,"ESTIMATED","2 Years","OBSERVATIONAL","To evaluate the ability of \\[68Ga\\]N188 to detect nectin-4 overexpression in patients with lung lesions.",[64,65],"Lung Cancer, Non-Small Cell","Lung Infection","2024-11-20",{"date":68,"type":69},"2024-11-25","ACTUAL",{"date":71,"type":69},"2024-11-21",{"date":73,"type":59},"2025-12-01",{"name":5,"class":6},1]